IVX invion limited

3.19%

9.7¢

Ann: Lupus clinical trial update, page-8

First 8 Last

Share
Profile

Follow
matakus

147 Posts.

6

08/09/14

14:47

Post #: 13940975
Share

Originally posted by sherriff25 ↑

I agree with you katy28,

If we don't get too carried away and overwhelmed with the information and look at the plain facts of the study then this has been successful to date.

There is and was to always be 4 cohorts with an increasing range of IV Cpn 10 from 10mg - 300mg (the cohorts initially detailed were to be 10mg, 30mg, 100mg, 300mg, however the levels of each cohort aren't set in stone).

Prior to this study we only have safety results on IV Cpn 10 at 5mg, 7.5mg, and 10mg. So to date with the results from cohort 2, 30mg IV we have some new and successful safety and tolerablility information.
The ph2a Rheumatoid Arthritis study (the most recent dud one!!) used Subcutaneous levels at 25mg and 75mg and they plucked the amounts of Cpn10 to use from two places, one that rhymes with class and the other from and Intravenous study that had a max dosage of 10mg. This is why I believe the Rheumatoid Arthritis study was flawed, because they jumped straight from IV to SC without and efficacy of Cpn10 actually working effectively with IV method.

I believe we are still on track for a successful trial. The dosage of IV Cpn10 will increase over the next two cohorts (which are included in this current study and shouldn't require any further Capital Raising) into uncharted territory for the safety and tolerability of Cpn10 given Intravenously and one would assume that with the increase doage that we should see some changes with the biomarkers of the patients with SLE.

I hope that this clears up some of the uncertainty and the over-reaction of the market to the market update. It is obvious that the sellers are uneducated on the study details and that the release is an actual positive release as this gives us new and previously unknown safety and tolerability for the 30mg dosage of Cpn10 given Intravenously, from this level we are looking to increase the dosage by 10x, so it is understandable that there should be gradual stepping stone jumps increases in dosage so that we don't jump from 10mg to 300mg, cross our fingers and hope for the best!!

So take home message from this is chill out, things are progressing as expected and wait for the exciting news from the next two trials, forget what the market is doing until then!!

Expand

Sherriff-well said.I think all the jumping up and down on Hot Copper last week with regards to releasing results has initiated a response by the company today.
I don't think they intended disclosing results until the final 2 cohorts were finalised in the forth quarter (which are the results regarding efficacy-we now know that cpn -10 is safe in lupus-a very good result)
Yes the uneducated sellers are their own worst enemy.

IVX Price at posting: 6.9¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

RNU

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

ASE

Astute delivers high-grade lithium hits at Red Mountain

SGQ

St George banks $5M from placement to ramp up Araxá Rare Earths Project

FTL

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

Most investors will get this earnings season wrong. Will you?

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

First 8 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 9.7¢		Change 0.003(3.19%)		Mkt cap ! $8.232M

Open	High	Low	Value	Volume
10.0¢	10.0¢	9.7¢	$3.425K	34.93K

Buyers (Bids)

No.	Vol.	Price($)
1	5200	9.7¢

Sellers (Offers)

Price($)	Vol.	No.
10.0¢	244080	3

View Market Depth

No.	Vol.	Price($)
1	84411	0.095
1	25000	0.093
1	42667	0.092
2	25666	0.090
1	40000	0.085

Price($)	Vol.	No.
0.100	244080	3
0.105	95332	1
0.110	57166	2
0.115	111043	3
0.120	45740	2

Last trade - 15.55pm 25/07/2025 (20 minute delay)

IVX (ASX) Chart

Ann: Lupus clinical trial update, page-8

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Astute delivers high-grade lithium hits at Red Mountain

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

Most investors will get this earnings season wrong. Will you?

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Lupus clinical trial update, page-8

Top Stories

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Astute delivers high-grade lithium hits at Red Mountain

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

Most investors will get this earnings season wrong. Will you?

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News